# Acute Asthma and Status Asthmaticus

## Pathophysiology

### Airway Obstruction Triad

Acute asthma exacerbation involves three mechanisms of airway obstruction working in concert. Bronchospasm is the contraction of airway smooth muscle, which narrows the lumen. Mucosal edema results from inflammatory mediator-driven swelling of the bronchial wall. Mucus plugging from hypersecretion of thick, tenacious mucus further obstructs the small airways. All three must be considered when designing a treatment strategy.

### Gas Trapping and Auto-PEEP

Expiratory airflow limitation leads to air trapping and dynamic hyperinflation — the patient cannot fully exhale before the next breath begins. This creates intrinsic PEEP (auto-PEEP), which increases the work of breathing and impairs venous return to the heart. Severe hyperinflation can cause hypotension, especially after intubation, by dramatically decreasing preload. Breath stacking is the mechanism underlying cardiovascular collapse in ventilated asthmatics, and understanding this physiology is essential to safe ventilator management.

### Inflammatory Cascade

Most asthma is driven by T-helper 2 (Th2) mediated eosinophilic inflammation. Mast cell degranulation releases histamine, leukotrienes, and prostaglandins. A late-phase response occurring 4 to 8 hours after the initial trigger can cause clinical deterioration after an initial period of improvement — this is why patients should not be discharged too quickly after responding to initial treatment. In severe and refractory asthma, including status asthmaticus, neutrophilic inflammation predominates.

## Severity Assessment

### Clinical Features of Severe/Critical Asthma

Several clinical features indicate severe or critical asthma. The inability to speak in full sentences is a red flag, and speaking in single words indicates a critical presentation. Accessory muscle use, diaphoresis, and tripod positioning reflect increased work of breathing. A silent chest — the absence of wheezing — is an ominous sign indicating that airflow is so minimal that no wheeze can be generated. Altered mental status, exhaustion, and inability to maintain respiratory effort suggest impending respiratory failure. Pulsus paradoxus greater than 25 mmHg suggests severe obstruction.

### Objective Parameters

Peak expiratory flow below 25 percent of predicted is life-threatening. SpO2 below 92 percent on room air indicates severe disease. A normal or elevated PaCO2 in an acutely dyspneic asthmatic is a danger sign — these patients should be hyperventilating with a low PaCO2, so a "normal" CO2 means the patient is tiring and can no longer compensate. Hypercapnia indicates impending respiratory failure. Lactate elevation may result from respiratory muscle fatigue and beta-agonist use rather than sepsis, and should not automatically trigger an infectious workup.

## Pharmacologic Management

### First-Line: Inhaled Beta-Agonists

Albuterol (salbutamol) by nebulization at 2.5 to 5 mg every 20 minutes for three doses, followed by continuous nebulization at 10 to 15 mg per hour, is the foundation of treatment. Continuous nebulization is preferred over intermittent dosing in moderate to severe exacerbations. For mild to moderate episodes, an MDI with spacer is equivalent to nebulizer delivery. Levalbuterol, the R-isomer of albuterol, has no proven clinical advantage over racemic albuterol despite marketing claims to the contrary.

### Ipratropium Bromide

Ipratropium at 0.5 mg nebulized every 20 minutes for three doses should be added to albuterol in severe exacerbations. Its anticholinergic mechanism complements the beta-agonist bronchodilation. The benefit is greatest in the first hour of treatment, with limited evidence supporting ongoing use afterward. In severe exacerbations, the number needed to treat to prevent one hospitalization is approximately 10.

### Systemic Corticosteroids

Corticosteroids should be given early because they take 4 to 6 hours to take effect — every hour of delay extends the exacerbation. Oral prednisone or prednisolone is equivalent to IV methylprednisolone for most patients. The adult dose is prednisone 40 to 60 mg, and the pediatric dose is prednisolone 1 to 2 mg/kg (maximum 60 mg). IV methylprednisolone 125 mg is used for severe exacerbations or patients unable to take oral medication. Dexamethasone at 0.6 mg/kg (maximum 16 mg) as a 1 to 2 day course is an emerging alternative to the traditional 5-day prednisone course, offering improved compliance.

The following table summarizes the key pharmacologic agents for acute asthma:

| Agent | Dose | Route | Key Notes |
|---|---|---|---|
| Albuterol | 2.5–5 mg q20 min × 3, then 10–15 mg/hr continuous | Nebulized | First-line; MDI+spacer equivalent for mild-moderate |
| Ipratropium | 0.5 mg q20 min × 3 | Nebulized | Add to albuterol in severe exacerbations; NNT ~10 |
| Prednisone | 40–60 mg (adult); 1–2 mg/kg peds (max 60 mg) | PO | Give early — takes 4–6 hours to work |
| Methylprednisolone | 125 mg | IV | For severe/unable to take PO |
| Dexamethasone | 0.6 mg/kg (max 16 mg) × 1–2 days | PO/IV | Improved compliance vs. 5-day prednisone |
| Magnesium sulfate | 2 g over 20 min | IV | For severe exacerbations (FEV1 < 25% predicted) |
| Epinephrine | 0.3–0.5 mg of 1:1,000 | IM | Severe exacerbation or anaphylaxis overlap |
| Ketamine | 1–2 mg/kg then 0.5–1 mg/kg/hr | IV | Best as induction agent if intubation needed |

### Magnesium Sulfate

IV magnesium at 2 grams over 20 minutes is indicated for severe exacerbations not responding to initial bronchodilator therapy. It works through smooth muscle relaxation via calcium channel antagonism. The best evidence supports its use in severe asthma with FEV1 below 25 percent predicted, with limited benefit in mild to moderate disease. Nebulized isotonic magnesium sulfate at 150 mg can be added to albuterol, providing a modest benefit in severe exacerbations based on the 3Mg trial. Monitoring for hypotension, flushing, and decreased deep tendon reflexes is important.

### Epinephrine

Intramuscular epinephrine at 0.3 to 0.5 mg of 1:1,000 is appropriate for severe exacerbations, especially when there is overlap with anaphylaxis. IV epinephrine infusion is reserved for peri-arrest situations or refractory bronchospasm. Nebulized racemic epinephrine can be tried when an upper airway edema component is present. Subcutaneous terbutaline at 0.25 mg is an alternative parenteral beta-agonist.

### IV Beta-Agonists

IV salbutamol (not available in the US) or IV terbutaline is used for refractory status asthmaticus. Continuous IV terbutaline is given as a loading dose of 10 mcg/kg followed by an infusion of 0.1 to 10 mcg/kg/min. Monitoring for tachycardia, hypokalemia, lactic acidosis, and myocardial ischemia is necessary. These agents are reserved for patients failing maximal inhaled therapy.

### Ketamine for Bronchospasm

Ketamine at a dissociative dose of 1 to 2 mg/kg IV followed by an infusion of 0.5 to 1 mg/kg/hr provides bronchodilation through catecholamine release and direct smooth muscle relaxation. The evidence is limited to case reports and small series without large RCTs. Its greatest utility is as an induction agent if intubation is needed, where its bronchodilatory properties are advantageous. Its role as a standalone bronchodilator infusion remains controversial.

### Heliox

Heliox — a helium-oxygen mixture at 70:30 or 80:20 ratios — reduces airway resistance due to the lower density of helium. This promotes laminar flow in turbulent airways, improving aerosol delivery and reducing work of breathing. It cannot be used if the FiO2 requirement exceeds 40 percent because the helium concentration becomes insufficient for benefit. Clinical evidence is limited and mixed, but it may serve as a useful bridge in severe obstruction.

## Non-Invasive Ventilation

BiPAP can reduce the work of breathing, improve bronchodilator delivery, and prevent intubation in acute asthma. Typical starting settings are IPAP 10 to 12 cmH2O and EPAP 5 cmH2O, titrated to effect. Caution is needed because air trapping may worsen with excessive IPAP or insufficient expiratory time. BiPAP is contraindicated in patients with altered mental status, vomiting, or inability to protect the airway. Close monitoring for clinical deterioration is essential, and intubation should proceed early if NIV is failing.

## Intubation of the Asthmatic

### When to Intubate

Intubation is indicated for clinical deterioration despite maximal medical therapy, altered mental status or inability to protect the airway, and respiratory arrest or peri-arrest. The decision should be clinical rather than based solely on blood gas values.

### Induction Considerations

Ketamine at 1.5 to 2 mg/kg IV is the preferred induction agent for its bronchodilatory properties. Either succinylcholine or rocuronium can be used for paralysis. Clinicians should prepare for post-intubation hypotension resulting from the loss of auto-PEEP compensation and the preload-reducing effects of positive-pressure ventilation. A pre-treatment IV fluid bolus of 500 to 1000 mL before induction helps mitigate this.

### Ventilator Management in Status Asthmaticus

The ventilator strategy in status asthmaticus centers on preventing hyperinflation. A low respiratory rate of 8 to 12 breaths per minute allows complete expiration. Low tidal volumes of 6 to 8 mL/kg reduce hyperinflation. A short inspiratory time with a long expiratory time (I:E ratio of 1:3 to 1:5) ensures adequate time for exhalation. Permissive hypercapnia — accepting an elevated PaCO2 of 60 to 80 mmHg as long as the pH remains above 7.2 — is a deliberate strategy to avoid fatal hyperinflation. Plateau pressures should be monitored with a goal below 30 cmH2O. If the patient becomes hemodynamically unstable after intubation, the first step is to disconnect from the ventilator and manually decompress the chest, then rule out tension pneumothorax.

| Ventilator Parameter | Target | Rationale |
|---|---|---|
| Respiratory rate | 8–12 breaths/min | Allow complete expiration |
| Tidal volume | 6–8 mL/kg IBW | Reduce hyperinflation |
| I:E ratio | 1:3 to 1:5 | Maximize expiratory time |
| Permissive hypercapnia | PaCO₂ 60–80 mmHg, pH > 7.2 | Avoid fatal hyperinflation |
| Plateau pressure | < 30 cmH₂O | Monitor for overdistension |
| PEEP | 0–5 cmH₂O | Avoid worsening auto-PEEP |

### Ketamine Infusion Post-Intubation

Sub-dissociative to dissociative doses of ketamine can augment bronchodilation post-intubation, allow reduced sedative requirements, and may improve ventilator synchrony. Bronchodilators should be continued via in-line nebulizer.

## Disposition

Discharge is appropriate when there is sustained improvement, peak expiratory flow above 70 percent predicted, SpO2 above 94 percent, and the patient can tolerate oral medications. A 5-day course of oral corticosteroids (or 2-day dexamethasone course) should be prescribed. Inhaler technique review, spacer prescription, and follow-up with a primary care provider or pulmonologist within 1 to 2 weeks are essential. ICU admission is indicated for intubated patients, those with persistent hypercapnia, hemodynamic instability, or ongoing severe symptoms despite 1 to 2 hours of aggressive treatment.

<image>A physiologic diagram showing the mechanism of auto-PEEP and dynamic hyperinflation in severe asthma. The left panel shows a normal breathing cycle with complete exhalation before the next breath. The right panel shows obstructed airways with incomplete exhalation and progressive air trapping across successive breaths, depicted as stacked volume-time curves with increasing end-expiratory lung volume. Arrows indicate trapped gas volume. A pressure gauge icon shows rising intrinsic PEEP from 0 to 15 cmH2O. Below, a cross-sectional view compares a normal bronchiole to one with bronchospasm, mucosal edema, and mucus plugging.</image>

<image>An emergency department treatment algorithm for acute asthma exacerbation. The flowchart begins with severity assessment (mild, moderate, severe, life-threatening) and branches into corresponding treatment tiers. Mild-moderate: albuterol MDI/nebulizer, oral steroids. Moderate-severe: continuous nebulization, ipratropium, IV steroids, magnesium sulfate. Life-threatening: add IV magnesium, epinephrine, consider NIV, prepare for intubation. Each tier includes reassessment points at 20-minute and 1-hour intervals. Disposition decisions are mapped to response categories: good response to discharge with follow-up, incomplete response to admission, poor response to ICU.</image>

<image>A ventilator screen display showing appropriate settings for the intubated status asthmaticus patient. The screen shows volume-control mode with respiratory rate 10, tidal volume 450 mL, I:E ratio 1:4, PEEP 0 cmH2O, and FiO2 100%. The flow-time waveform demonstrates incomplete return to baseline before the next breath (indicating auto-PEEP), and the pressure-time waveform shows a plateau pressure of 28 cmH2O. Annotations point out the auto-PEEP measurement technique and the importance of permissive hypercapnia with an ABG showing pH 7.25, PaCO2 68.</image>

## Clinical Pearls

A "normal" PaCO2 in an acutely dyspneic asthmatic is a red flag — it means the patient is tiring and cannot maintain compensatory hyperventilation. A silent chest means no airflow, not clinical improvement, and is a pre-arrest finding. Corticosteroids should be given early because they take 4 to 6 hours to work, and every hour of delay extends the exacerbation. Magnesium sulfate works best in severe exacerbations, with marginal benefit in mild disease. Post-intubation cardiovascular collapse in asthmatics is usually caused by auto-PEEP, not tension pneumothorax — the first step is to disconnect the ventilator and manually decompress. Permissive hypercapnia is safe and essential in ventilating the obstructed patient, because chasing normal CO2 causes fatal hyperinflation. Beta-agonist-induced lactic acidosis can mimic sepsis, so antibiotics should not be reflexively started based on lactate alone. While ketamine is physiologically appealing as an induction agent for asthmatic intubation, the evidence for ketamine infusion as a standalone bronchodilator remains weak.

## References

- National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 4. *NHLBI*. 2020.
- Goodacre S, et al. 3Mg Trial: Nebulized magnesium in acute asthma. *Lancet Respir Med*. 2013;1:293-300.
- Rowe BH, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. *Cochrane Database Syst Rev*. 2000.
- Leatherman JW, McArthur C, Shapiro RS. Effect of prolongation of expiratory time on dynamic hyperinflation in mechanically ventilated patients with severe asthma. *Crit Care Med*. 2004;32:1542-1545.
- Pardue Jones B, et al. Ketamine for acute asthma exacerbation: a systematic review. *J Emerg Med*. 2016;51:485-492.